Issue 123, 2015

Co-delivery of siRNA and doxorubicin to cancer cells from additively manufactured implants

Abstract

Tumors in load bearing bone tissue are a major clinical problem, in part because surgical resection invokes a dilemma whether to resect aggressively, risking mechanical failure, or to resect conservatively, risking cancer recurrence due to residual malignant cells. A chemo-functionalized implant, capable of physically supporting the void while killing residual cancer cells, would be an attractive solution. Here we describe a novel additively manufactured implant that can be functionalized with chitosan/siRNA nanoparticles. These induce long term gene silencing in adjacent cancer cells without showing toxicity to normal cells. When scaffolds are functionalized with siRNA/chitosan nanoparticles and doxorubicin in combination, their effects synergized leading to cancer cell death. This technology may be used to target resistance genes by RNA interference and thereby re-sensitizing the cancer cells to co-delivered chemotherapy.

Graphical abstract: Co-delivery of siRNA and doxorubicin to cancer cells from additively manufactured implants

Supplementary files

Article information

Article type
Paper
Submitted
10 Nov 2015
Accepted
12 Nov 2015
First published
16 Nov 2015
This article is Open Access
Creative Commons BY license

RSC Adv., 2015,5, 101718-101725

Author version available

Co-delivery of siRNA and doxorubicin to cancer cells from additively manufactured implants

M. Chen, M. Ø. Andersen, P. Dillschneider, C. Chang, S. Gao, D. Q. S. Le, C. Yang, S. Hein, C. Bünger and J. Kjems, RSC Adv., 2015, 5, 101718 DOI: 10.1039/C5RA23748C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements